The effect of hyaluronic acid (Cicatridine) on healing and regeneration of the uterine cervix and vagina and vulvar dystrophy therapy

J. Markowska1, R. Madry2, A. Markowska3

1Chair and Department of Oncology, 2Department of Perinatology and Gynaecology gynaecological Oncology and Obstetrics Center, Poznan University of Medical Sciences in Poznan (Poland)


Procedures aimed at the treatment of precancerous lesions and ectopia on the uterine cervix are frequently linked to lesions of anatomical structures. The application of hyaluronic acid (Cicatridine vaginal ovules) promotes accelerated healing of the uterine cervix and acquisition of a normal shape in the uterine cervix canal. Local application of hyaluronic acid in the vagina following radiotherapy due to cancer in the uterine cervix or endometrium favourably affects the healing of post-irradiation lesions in the vagina and improves quality of life. Over 90% of patients responded positively to the application of hyaluronic acid in the form of a cream on dystrophic lesions in the vulva. Hyaluronic acid aids the healing process of post-procedural wounds in the uterine cervix, following radiotherapy applied due to cancer of the uterine cervix, endometrium and in vulvar dystrophy.

Key words: Hyaluronic acid; Uterine cervix; Dysplasia of uterine cervix; Radiotherapy; Endometrial carcinoma; Cancer of uterine cervix; Dystrophy.


Uterine cervix treatment of precancerous lesions or ectopia are linked to surgical, thermal or electric trauma. A significant proportion of females after radiotherapy due to cervical or endometrial cancer suffer post-irradiation reactions in the vagina, involving the thinning and an increasing fragility of the vaginal walls, vasodilation and atrophy. This may lead to a narrowing of the vaginal walls, its adhesion, ulcerations and even to the formation of vesico-vaginal and recto-vaginal fistulas [1, 2]. At the same time, irradiation linked to surgical castration induced by the procedure reduces several functions, thus affecting the quality of life [3-5].

Reparative and remodelling processes within the uter­ine cervix manifest a variable duration, depending on the type of therapeutic intervention.

During menopause, mainly due to oestrogen deficiency, a significant proportion of women also manifest vulvar lesions. The amount of adipose tissue becomes reduced, collagen fibres disappear, the epithelium becomes thinner and its sublayer demonstrates traits of chronic inflamma­tion, lichen sclerosus. At the time morphotic elements of the vulva undergo atrophy: the small pudendal lip and cli­toris develop dystrophic lesions. Occasionally, the epithe­lium is white, thickened and cracked, which is character­istic of a hypertrophic dystrophy [6].

Hyaluronic acid, the main component of Cicatridine, acts on two levels — water retention in the tissues and through binding to proteins and the formation of a proteo­glycan network. Thus it improves tissue hydration and the

Revised manuscript accepted for publication April 6, 2010 import of nutrients to the tissue. This results in a normal tissue turgor, its improved elasticity and in epithelial regeneration in atrophy and dystrophy of vaginal mucosa. Through its presence in the extra-cellular matrix and due to its modulating potential as well as due to its promotion of capillary sprouting, hyaluronic acid favourably affects healing processes, including the formation of a normal epithelium [7-9].

The study was aimed at evaluating Cicatridine, applied in the form of ovules (1 ovule contains: 0.005 g sodium salt of hyaluronic acid, 0.06 g — Centella asiatica oil extract (Hydrocotyle asiatica L., Hydrocotyle repanda Pers., Gotu kola), 0.06 g — calendula oil extract, 0.06 g — aloe oil extract, 0.002 g — tea-tree essential oil) in the course of healing and reparation processes following surgical proce­dures on the uterine cervix, and following radiotherapy applied due to cervical and endometrial cancer as well as at the evaluation of hyaluronic acid applied in the form of a cream (1 g of which contains 0.002 g sodium salt of hyaluronic acid) used in vulvar dystrophy therapy.

Patients and Methods

The total number of 213 women, including 109 patients fol­lowing procedures involving the uterine cervix due either to CIN I — CIN III (following electroconization) or ectopy of the uterine cervix (following electrocoagulation and cryotherapy), 53 women following radiotherapy due to cancer of the uterine cervix or cancer of the endometrium and 51 women in whom earlier vulvar dystrophy was histologically confirmed.

A control group consisted of 86 patients following procedures on the uterine cervix, following radiotherapy or showing vulvar dystrophy, in whom the studied preparation was not applied. The analysed material is listed in Table 1

Table 1. — Patients and the control group

Groups of patients Examined group % Control group %
Patients following uterine cervix procedures 109 51.17 42 48.84
with CIN I — CIN III, subjected to electroconization 32 9
with ectopy of the uterine cervix, subjected to electroconization 43 15
with ectopy of the uterine cervix, subjected to cryotherapy 34 18
Patients following radiotherapy 53 24.88 24 27.91
following radiotherapy due to cancer of the uterine cervix 16 12
following radiotherapy due to cancer of the endometrium 37 12
Patients with vulvar dystrophy 51 23.94 20 23.26
Total 213 100.00 86 100.00

Table 2. — Women treated with the studied preparation vs control group following procedures on the uterine cervix

Examined group Control group
After Weeks After 3 months After 6 Weeks After 3 months
N N % N % N N % N %
Patients with CIN I — CIN III subjected to electroconization 32 27 84.38* 32 100.00 9 5 55.56* 8 88.89
Patients with ectopy of the uterine cervix subjected to electrocoagulation 43 38 88.37 40 93.02 15 11 73.33 12 80.00
Patients with ectopy of the uterine cervix subjected to cryotherapy 34 34 100.00* 34 100.00 18 12 66.67* 18 100.00
Total 109 99 90.83* 106 97.25 42 28 66.67* 38 90.48

* p < 0.05

In patients following procedures on the uterine cervix aimed at accelerated re-epithelization, the application of hyaluronic acid in the form of vaginal ovules was started 24 hours after the operation.

In patients following radiotherapy, indications for the treat­ment involved the detection of inflammatory/necrotic lesions in the vagina, adhesions of vaginal walls and complaints associat­ed with coitus after the completion of brachytherapy. Vaginal ovules of the preparation were applied once daily, in the evening for ten subsequent days and, then, for a period of one month, every second day and, in cases showing improvement, for a fur­ther month every third day.

In women with vulvar dystrophy cream containing hyaluron­ic acid was applied for a month; it was applied to affected sites twice a day. In cases of improvement the procedure was recom­mended to be continued for a further three months and, then, for two months, applying it at night. Patients in the control group applied no therapy following procedures on the uterine cervix and radiotherapy. Women in the control group and those affect­ed by vulvar dystrophy included patients who following diagno­sis did not want to participate in the therapy and decided to fol­low hygienic procedures only.

Results of the treatment were evaluated after six weeks and three months, and women treated with vaginal ovules of the preparation were evaluated by visual examination of the uterine cervix and/or vagina and patient feeling. In women with vulvar dystrophy treated with hyaluronic acid, evaluation was conduct­ed one, three and six months after termination of the therapy by visual inspection and comfort of the patients.

Statistical evaluation was performed by statistical software, using the Wilcoxon and the Mann-Whitney U tests.


Most of the examined women (99-90.83%) in whom Cicatridine vaginal ovules were applied following opera­tions on the uterine cervix due to CIN I-CIN III and ectopy of uterine cervix after six weeks demonstrated a healed cervix with no deformations or endometriotic foci and in none of the cases did the cervical canal outlet demonstrate any narrowing.

In the control group only 28 women (66.67%) achieved a similar result. Following three months, 106 women of the treated group (97.25%) had a healed cervix while in the control group the fraction of patients was only slight­ly lower (90.48%) (Table 2).

In patients following radiotherapy treated with vaginal ovules of the preparation a healed vagina was noted in 12 women (22.64%) and improvement was detected in 45 women (84.91%). In the control group no healing or improvement could be detected in any of the patients dur­ing the three-month observation period (Table 3).

In the group of 51 women with vulvar dystrophy a pos­itive response to treatment with cream containing the examined substance was noted in 46 patients (90.2%) and in a significant fraction (64.71%) the group consisted of healthy, asymptomatic patients. In patients not exposed to cream, hygienic management resulted in a response in 65% women but in such cases just improvement, not total elimination of the symptoms could be noted (Table 4).


Procedures on the uterine cervix, performed due to pre-cancerous lesions (CIN) or ectopy, are linked to a more or less extensive tissue lesion, associated with var­ious complaints, including bleeding, spotting, excessive discharge, fibrosis, endometriosis, narrowing of the uter­ine cervical canal and a psychological discomfort reflect­ing the fear that sexual contact may negatively affect the healing process.

Table 3. — Women administered the examined preparation vs the control group following radiotherapy due to cancer of the uterine cervix and/or cancer of the endometrium

Examined group Control group
Healing after 3 months Improvement after 3 months Healing after 3 months Improvement after 3 months
N N % N % N N % N %
Patients following radiotherapy due to cancer of the uterine cervix 16 4 25.00 13 81.25* 12 0 0.00 0 0.00*
Patients following radiotherapy due to endometrial cancer 37 8 21.62 32 86.49* 12 0 0.00 0 0.00*
Total 53 12 22.64 45 84.91* 24 0 0.00 0 0.00*

Table 4. — Results of observation in patients affected by vulvar dystrophy (preparation vs placebo).

Examined group Examined group
N % N %
Healthy asymptomatic women 33 64.71* 0 0.00*
Improvement 13 25.49* 13 65.00*
Stabilization 1 1.96 0 0.00
Deterioration 4 7.84 7 35.00
Total 51 100.00 20 100.00
Positive response 46 90.20* 13 65.00*

* p < 0.05

The results of our earlier studies, on a lower number of patients, indicated that locally applied Cicatridine prepara­tion accelerated repair processes to a variable extent, depending on the type of procedure on the uterine cervix [10]. In a higher number of women following procedures on the uterine cervix we have confirmed that hyaluronic acid accelerates the healing processes and prevents narrow­ing of the canal in the uterine cervix. It is quite possible that this involves the same mechanism which prevents develop­ment of adhesions after application of hyaluronic acid fol­lowing abdominal operations in an animal model [11].

Radiotherapy, used following oncological surgery in the treatment of uterine cervix cancer or cancer of the endometrium, induces port-irradiation injury overlapping with castration-linked hypooestrogenism. This represents a significant problem of deteriorated life quality while the decreasing pH in the vagina is linked to reduced sexual satisfaction [1-4, 12].

Studies of Katz [1] and those of Lorenz et al. [2] demonstrated that irradiation induced dryness and nar­rowing of the vagina and in 26% of females it resulted in late post-irradiation reactions, which had a strong nega­tive impact on sexual function, and in this way decreasing the quality of life.

Application of vaginal ovules with the studied prepara­tion has induced healing of the vaginal lesions in over 20% of the patients (Table 3) and an improved vaginal outlook and subjective perception in over 80% of the patients. Such activity has been confirmed by other authors both in animal models and in the course of sec­ond-look operations, which have demonstrated the anti­adhesion effects of hyaluronic acid [11, 13].

In the therapy of vaginal dystrophy we see a continuous introduction of novel therapeutic methods. Ayhan et al. [6] obtained a satisfactory clinical response to the appli­cation of testosterone and corticoids in such patients but they were not accompanied by histological improvement. In the last ten years the photodynamic method of treating vulvar pathology

has been introduced, which proved to be effective following a variable period of application (on average after 6 months) but the disease relapsed [14, 15].

In conclusion, intense application of Cicatridine is non- invasive, easy to implement and inexpensive, and in our group of 51 patients it resulted in a favourable effect of the treatment in over 90% of the patients.



  1. Katz A.: “Interventions for sexuality after pelvic radiation therapy and gynecological cancer”. Cancer J., 2009, 75, 45.
  2. Lorenz E., Strickert T., Hagen B.: “Cervical carcinoma: postoper­ative radiotherapy: fifteen year experience in a Norvegian health region”. Int. J. Gynecol. Cancer, 2009, 19, 1595.
  3. Guaschino S., Benvenuti C.: “SOPHY Study Group SOPHY proj­ect: an observational study of vaginal pH and lifestyle in women of different ages and different physiopathological conditions. Part. I”. Minerva Ginecol., 2008, 60, 105.
  4. Jensen P., Groenvold M., Klee M., Thranov I., Petersen M.A., Machin D.: “Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2003, 56, 937.
  5. Nashiro T., Yagi C., Hirakara M., Inamine M., Nagai Y., Sakumoto K. et al.: “Concurrent chemoradiation for locally advanced squa­mous cell carcinoma of the vagina: case series and literature review”. Int. J. Clin. Oncol., 2008, 13, 335.
  6. Ayhan A., Tuncer Zs., Kaya H.: “Vulvar dystrophy: an evolution of 285 cases”. Eur. J. Gynaecol. Oncol., 1997, 18, 139.
  7. Jackson S., James M., Abrams P.: “The effect of oestradiol on vagi­nal collagen metabolism in postmenopausal women with genuine stress incontinence”. BJOG, 2002, 109, 339.
  8. Gerdin B., Hallgren R.: “Dynamic role of hyaluronan (HA4) in connective tissue activation and inflammation”. J. Intern. Med., 1997, 242, 49.
  9. Kaya G., Tran C., Sorg O., Hotz R., Grand D., Carraux P. et al.: “Hyaluronate fragments reverse skin atrophy by a CD44 — depend­ent mechanism”. PLoS Med., 2006, 3, 493.
  10. Markowska J., Markowska A., M dry R.: “Evaluation of Cicatridine efficacy in healing and repairing process of uterine cervix, vagina and vulva-open no-randomized clinical study”. Gin. Pol., 2008, 79, 494.
  11. Falabella C.A., Chen W.: “Cross-linked hyaluronic acid films to reduce intra-abdominal postsurgical adhesions in an experimental model”. Dig. Surg., 2010, 26, 476.
  12. Greimel E.R., Winter R., Kapp K.S., Haas J.: “Quality of life and sexual functioning after cervical cancer treatment: a long-term fol­low-up study”. Psychooncology, 2009, 18, 476.
  13. Lundroff P., van Geldorp H., Tronstad S.E., Lalos 0., Larsson B., Johns D.B., di Zerega G.S. et al:. “Reduction of post-surgical adhesions with ferrie hyaluronate gel: a European study”. Hum. Reprod., 2001, 16, 1982.
  14. Hillemanns R, Untch M., Prove F., Baumgartner R., Hillemanns M., Korell M. et al: “Photodynamic therapy of vulvar lichen scle- rosus with 5-aminolevulinic acid”. Obstet. Gynecol., 1999, 93, 71.
  15. Hillemanns P., Wang X., Staehle S., Michels W., Dannecker C. et al: “Evaluation of different teratment modalities for vulvar intraepithelial neoplasia (VIN): CO2 laser vaporization, photody­namic therapy, excision and vulvectomy”. Gynecol. Oncol., 2006, 100, 271.

Информация на сайте предназначена для профессиональной деятельности фармацевтических и медицинских работников. Официальный сайт компании ООО "ЕВРОЛЕК". Все права защищены, 2013-2014.

Укоротить ссылку
Погода в Киеве